Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

NASDAQ:LPTX

Leap Therapeutics, Inc.

Last Close

3.10

01/05 20:00

Market Cap

83.72M

Beta: 0.74

Volume Today

151.39K

Avg: 600.93K

PE Ratio

−1.13

PFCF: −1.85

Filings Not Available

Please Sign In To Use The Chat